100 results on '"Meert, L."'
Search Results
2. POS0410 A BIOPSYCHOSOCIAL APPROACH TO PHENOTYPE KNEE OSTEOARTHRITIS PATIENTS AWAITING TOTAL KNEE ARTHROPLASTY: A CROSS-SECTIONAL STUDY
- Author
-
Vervullens, S., primary, Meert, L., additional, Van der Nest, G., additional, Verbrugghe, J., additional, Verdonk, P., additional, Rahussen, F., additional, Smeets, R., additional, and Meeus, M., additional
- Published
- 2023
- Full Text
- View/download PDF
3. Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer.
- Author
-
Maertens, J., Lodewyck, T., Donnelly, J.P., Chantepie, S., Robin, C., Blijlevens, N.M., Turlure, P., Selleslag, D., Baron, F., Aoun, M., Heinz, W.J., Bertz, H., Ráčil, Z., Vandercam, B., Drgona, L., Coiteux, V., Llorente, C.C., Schaefer-Prokop, C.M., Paesmans, M., Ameye, L., Meert, L., Cheung, K.J., Hepler, D.A., Loeffler, J., Barnes, R., Marchetti, O., Verweij, P.E., Lamoth, F., Bochud, P.Y., Schwarzinger, M., Cordonnier, C., Maertens, J., Lodewyck, T., Donnelly, J.P., Chantepie, S., Robin, C., Blijlevens, N.M., Turlure, P., Selleslag, D., Baron, F., Aoun, M., Heinz, W.J., Bertz, H., Ráčil, Z., Vandercam, B., Drgona, L., Coiteux, V., Llorente, C.C., Schaefer-Prokop, C.M., Paesmans, M., Ameye, L., Meert, L., Cheung, K.J., Hepler, D.A., Loeffler, J., Barnes, R., Marchetti, O., Verweij, P.E., Lamoth, F., Bochud, P.Y., Schwarzinger, M., and Cordonnier, C.
- Abstract
Item does not contain fulltext, BACKGROUND: Empiric antifungal therapy is considered the standard of care for high-risk neutropenic patients with persistent fever. The impact of a preemptive, diagnostic-driven approach based on galactomannan screening and chest computed tomography scan on demand on survival and on the risk of invasive fungal disease (IFD) during the first weeks of high-risk neutropenia is unknown. METHODS: Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and allogeneic hematopoietic cell transplant recipients were randomly assigned to receive caspofungin empirically (arm A) or preemptively (arm B), while receiving fluconazole 400 mg daily prophylactically. The primary end point of this noninferiority study was overall survival (OS) 42 days after randomization. RESULTS: Of 556 patients recruited, 549 were eligible: 275 in arm A and 274 in arm B. Eighty percent of the patients had AML or MDS requiring high-dose chemotherapy, and 93% of them were in the first induction phase. At day 42, the OS was not inferior in arm B (96.7%; 95% confidence interval [CI], 93.8%-98.3%) when compared with arm A (93.1%; 95% CI, 89.3%-95.5%). The rates of IFDs at day 84 were not significantly different, 7.7% (95% CI, 4.5%-10.8%) in arm B vs 6.6% (95% CI, 3.6%-9.5%) in arm A. The rate of patients who received caspofungin was significantly lower in arm B (27%) than in arm A (63%; P < .001). CONCLUSIONS: The preemptive antifungal strategy was safe for high-risk neutropenic patients given fluconazole as prophylaxis, halving the number of patients receiving antifungals without excess mortality or IFDs. Clinical Trials Registration. NCT01288378; EudraCT 2010-020814-27.
- Published
- 2023
4. The effect of one dry needling session on pain, central pain processing, muscle co-contraction and gait characteristics in patients with knee osteoarthritis: a randomized controlled trial
- Author
-
Vervullens, S., Vervullens, S., Meert, L., Baert, I., Delrue, N., Heusdens, C.H.W., Hallemans, A., Van Criekinge, T., Smeets, R.J.E.M., De Meulemeester, K., Vervullens, S., Vervullens, S., Meert, L., Baert, I., Delrue, N., Heusdens, C.H.W., Hallemans, A., Van Criekinge, T., Smeets, R.J.E.M., and De Meulemeester, K.
- Abstract
Objectives: To assess the immediate and three days postintervention effect of one dry needling session compared to one sham needling session on pain, central pain processing, muscle co-contraction and spatiotemporal parameters during gait in knee osteoarthritis patients.Methods: A double-blind randomized controlled trial was conducted. Sixty-one knee osteoarthritis patients were randomly assigned to the dry needling or sham needling group. Primary outcomes were pain and central pain processing. Secondary outcomes included muscle co-contraction and spatiotemporal parameters during gait. Patients were assessed at baseline and 15 min after the intervention, and pain also three days after the intervention. Linear mixed models were used to examine between- and within-group differences.Results: No significant between-group differences for pain were found, but within-group scores showed a significant decrease 15 min after sham needling and three days after dry needling. The mean conditioned pain modulation effect measured at the m. Trapezius worsened significantly 15 min after sham needling compared to after dry needling (between-group difference). However, individual conditioned pain modulation percentage scores remained stable over time. Various significant within-group differences were found 15 min after sham needling: a decrease of conditioned pain modulation measured at m. Quadriceps and m. Trapezius and stride- and step-time scores, and an increase in step length and widespread pain pressure threshold. A significant decrease in muscle co-contraction index of the m. Vastus Medialis and Semitendinosus was found as within-group difference 15 min after dry needling.Conclusions: Dry needling has no larger effect on pain, central pain processing, muscle co-contraction and gait pattern 15 min and three days postintervention compared to sham needling. Mean conditioned pain modulation scores worsened after sham needling compared to after dry needling. Further research remains
- Published
- 2022
5. Personal influencing factors for pressure pain threshold in healthy people: A systematic review and meta-analysis
- Author
-
Vervullens, S., Haenen, V., Meert, L., Meeus, M., Smeets, R.J.E.M., Baert, I., Mertens, M.G.C.A.M., Vervullens, S., Haenen, V., Meert, L., Meeus, M., Smeets, R.J.E.M., Baert, I., and Mertens, M.G.C.A.M.
- Abstract
All studies that investigated personal factors influencing pressure pain threshold (PPT) in healthy people were synthesized. Data was summarized, and risk of bias (RoB) and level of evidence were determined. Results were pooled per influencing factor, grouped by body region and included in meta-analyses. Fifty-four studies were eligible. Five had low, nine moderate, and 40 high RoB. Following meta-analyses, a strong conclusion was found for the influence of scapular position, a moderate for the influence of gender, and a weak for the influence of age (shoulder/arm region) and blood pressure on PPT. In addition, body mass index, gender (leg region), alcohol consumption and pain vigilance may not influence PPT. Based on qualitative summary, depression and meno-pause may not influence PPT. For other variables there was only preliminary or conflicting evidence. However, caution is advised, since the majority of included studies showed a high RoB and several were not eligible to include in meta-analyses. Heterogeneity was high in the performed meta-analyses, and most conclusions were weak. More standardized research is necessary.
- Published
- 2022
6. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)
- Author
-
Willemze, R., Suciu, S., Muus, P., Halkes, C. J. M., Meloni, G., Meert, L., Karrasch, M., Rapion, J., Vignetti, M., Amadori, S., de Witte, T., and Marie, J. P.
- Published
- 2014
- Full Text
- View/download PDF
7. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study
- Author
-
Herbrecht, R, Maertens, J, Baila, L, Aoun, M, Heinz, W, Martino, R, Schwartz, S, Ullmann, A J, Meert, L, Paesmans, M, Marchetti, O, Akan, H, Ameye, L, Shivaprakash, M, and Viscoli, C
- Published
- 2010
- Full Text
- View/download PDF
8. Experimentally generated footprints in sand: analysis and consequences for the interpretation of fossil and forensic footprints
- Author
-
D'Aout, K., Meert, L., Van Gheluwe, B., De Clercq, D., and Aerts, P.
- Subjects
Foot -- Properties ,Footprints, Fossil -- Identification and classification ,Gait -- Analysis ,Walking -- Physiological aspects ,Anthropology/archeology/folklore - Abstract
Fossilized footprints contain information about the dynamics of gait, but their interpretation is difficult, as they are the combined result of foot anatomy, gait dynamics, and substrate properties. We explore how footprints are generated in modern humans. Sixteen healthy subjects walked on a solid surface and in a layer of fine-grained sand. In each condition, 3D kinematics of the leg and foot were analyzed for three trials at preferred speed, using an infrared camera system. Additionally, calibrated plantar pressures were recorded. After each trial in sand, the depth of the imprint was measured under specific sites. When walking in sand, subjects showed greater toe clearance during swing and a 7[degrees] higher knee yield during stance. Maximal pressure was the most influential factor for footprint depth under the heel. For other foot zones, a combination of factors correlates with imprint depth, with pressure impulse (the pressure-time integral) gaining importance distally, at the metatarsal heads and the hallux. We conclude that footprint topology cannot be related to a single variable, but that different zones of the footprint reflect different aspects of the kinesiology of walking. Therefore, an integrated approach, combining anatomical, kinesiological, and substrate-mechanical insights, is necessary for a correct interpretation. Am J Phys Anthropol 141:515-525, 2010. [c] 2009 Wiley-Liss, Inc. KEY WORDS ichnology; substrate; foot function; plantar pressure DOI 10.1002/ajpa.21169
- Published
- 2010
9. POS1096 THE EFFECT OF ONE DRY NEEDLING SESSION ON PAIN AND CENTRAL PAIN PROCESSING IN PATIENTS WITH KNEE OSTEOARTHRITIS: A RANDOMIZED CONTROLLED TRIAL
- Author
-
Vervullens, S., primary, Meert, L., additional, Baert, I., additional, Delrue, N., additional, Heusdens, K., additional, Hallemans, A., additional, Van Criekinge, T., additional, Smeets, R., additional, and De Meulemeester, K., additional
- Published
- 2021
- Full Text
- View/download PDF
10. Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study
- Author
-
Baron, F., Efficace, F., Cannella, L., Muus, P., Trisolini, S., Halkes, C.J., Fazi, P., Vignetti, M., Marie, J.P., Chiusolo, P., Velden, W.J. van der, La Sala, E., Vitolo, U., Thomas, X., Lefrere, F., Raimondo, F. Di, Bourhis, J.H., Specchia, G., Guimaraes, J.E., Allione, B., Vrhovac, R., Ferrara, F., Stevens-Kroef, M.J., Meert, L., Witte, T.J. de, Willemze, R., Amadori, S., Suciu, S., Baron, F., Efficace, F., Cannella, L., Muus, P., Trisolini, S., Halkes, C.J., Fazi, P., Vignetti, M., Marie, J.P., Chiusolo, P., Velden, W.J. van der, La Sala, E., Vitolo, U., Thomas, X., Lefrere, F., Raimondo, F. Di, Bourhis, J.H., Specchia, G., Guimaraes, J.E., Allione, B., Vrhovac, R., Ferrara, F., Stevens-Kroef, M.J., Meert, L., Witte, T.J. de, Willemze, R., Amadori, S., and Suciu, S.
- Abstract
Item does not contain fulltext, We provide a long-term evaluation of patients enrolled in the EORTC/GIMEMA AML-10 trial which included a total of 2157 patients, 15-60 years old, randomized to receive either daunorubicin (DNR, 50 mg/m(2) ), mitoxantrone (MXR, 12 mg/m(2) ), or idarubicin (IDA, 10 mg/m(2) ) in addition to standard-dose cytarabine and etoposide for induction chemotherapy and intermediate dose cytarabine for consolidation. Younger patients who reached complete remission with complete (CR) or incomplete (CRi) recovery were then scheduled to receive an allogeneic hematopoietic stem cell transplantation (HSCT). That was if they had a HLA-identical sibling donor; in all other cases, an autologous HSCT had to be administered. At an 11-year median follow-up, the 5-year, 10-year and 15-year overall survival (OS) rates were 33.2%, 30.1% and 28.0%, respectively. No significant difference between the three randomized groups regarding OS was observed (P = .38). In young patients, 15-45 years old, no treatment difference (P = .89) regarding OS was observed, while in patients 46-60 years old, MXR and IDA groups had a trend for a longer OS as compared to the DNR group (P = .029). Among younger patients without a favorable MRC cytogenetic risk subgroup who achieved a CR/CRi after induction chemotherapy, those with a HLA-identical sibling donor had higher 10-year and 15-year OS rates than those without. In older patients who reached CR/CRi, the long-term outcomes of those with or without a donor was similar. In conclusion, long-term outcomes of the study confirmed similar OS in the three randomized groups in the whole cohort of patients.
- Published
- 2020
11. Survival improvement over time of 960 s-AML patients included in 13 EORTC-GIMEMA-HOVON trials
- Author
-
Ramadan, SM, Suciu, S, Stevens-Kroef, MJ, Willemze, R, Amadori, S, Witte, T, Löwenberg, Bob, Muus, P, Labar, B, Meert, L, de Schaetzen, G, Meloni, G, Leone, G, Vignetti, M, Marie, JP, Lübbert, M, Baron, F, Ramadan, SM, Suciu, S, Stevens-Kroef, MJ, Willemze, R, Amadori, S, Witte, T, Löwenberg, Bob, Muus, P, Labar, B, Meert, L, de Schaetzen, G, Meloni, G, Leone, G, Vignetti, M, Marie, JP, Lübbert, M, and Baron, F
- Published
- 2020
12. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients
- Author
-
Viscoli, C, Herbrecht, R, Akan, H, Baila, L, Sonet, A, Gallamini, A, Giagounidis, A, Marchetti, O, Martino, R, Meert, L, Paesmans, M, Ameye, L, Shivaprakash, M, Ullmann, A J, and Maertens, J
- Published
- 2009
13. Publisher Correction: Mediator complex interaction partners organize the transcriptional network that defines neural stem cells (Nature Communications, (2019), 10, 1, (2669), 10.1038/s41467-019-10502-8)
- Author
-
Quevedo Calero, M. (Martí), Meert, L (Lize), Dekker, M. (Mike), Dekkers, D.H. (Dick), Brandsma, J.H. (Johan), Berg, D.L.C. (Debbie) van den, Ozgur, Z. (Zeliha), IJcken, W.F.J. (Wilfred) van, Demmers, J.A.A. (Jeroen), Fornerod, M.W.J. (Maarten), Poot, R.A. (Raymond), Quevedo Calero, M. (Martí), Meert, L (Lize), Dekker, M. (Mike), Dekkers, D.H. (Dick), Brandsma, J.H. (Johan), Berg, D.L.C. (Debbie) van den, Ozgur, Z. (Zeliha), IJcken, W.F.J. (Wilfred) van, Demmers, J.A.A. (Jeroen), Fornerod, M.W.J. (Maarten), and Poot, R.A. (Raymond)
- Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- Published
- 2019
- Full Text
- View/download PDF
14. Mediator complex interaction partners organize the transcriptional network that defines neural stem cells
- Author
-
Quevedo Calero, M. (Martí), Meert, L (Lize), Dekker, M. (Mike), Dekkers, D.H. (Dick), Brandsma, J.H. (Johan), Berg, D.L.C. (Debbie) van den, Ozgur, Z. (Zeliha), IJcken, W.F.J. (Wilfred) van, Demmers, J.A.A. (Jeroen), Fornerod, M.W.J. (Maarten), Poot, R.A. (Raymond), Quevedo Calero, M. (Martí), Meert, L (Lize), Dekker, M. (Mike), Dekkers, D.H. (Dick), Brandsma, J.H. (Johan), Berg, D.L.C. (Debbie) van den, Ozgur, Z. (Zeliha), IJcken, W.F.J. (Wilfred) van, Demmers, J.A.A. (Jeroen), Fornerod, M.W.J. (Maarten), and Poot, R.A. (Raymond)
- Abstract
The Mediator complex regulates transcription by connecting enhancers to promoters. High Mediator binding density defines super enhancers, which regulate cell-identity genes and oncogenes. Protein interactions of Mediator may explain its role in these processes but have not been identified comprehensively. Here, we purify Mediator from neural stem cells (NSCs) and identify 75 protein-protein interaction partners. We identify super enhancers in NSCs and show that Mediator-interacting chromatin modifiers colocalize with Mediator at enhancers and super enhancers. Transcription factor families with high affinity for Mediator dominate enhancers and super enhancers and can explain genome-wide Mediator localization. We identify E-box transcription factor Tcf4 as a key regulator of NSCs. Tcf4 interacts with Mediator, colocalizes with Mediator at super enhancers and regulates neurogenic transcription factor genes with super enhancers and broad H3K4me3 domains. Our data suggest that high binding-affinity for Mediator is an important organizing feature in the transcriptional network that determines NSC identity.
- Published
- 2019
- Full Text
- View/download PDF
15. Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase 1/11 results of the EORTC/GIMEMA AML-14A trial
- Author
-
Selleslag, D., Suciu, S., Meloni, G., Muus, P., Halkes, C.J.M., Venditti, A., Ramadan, S.M., Pruijt, H., Meert, L., Vignetti, M., Marie, J.P., Wittnebel, S., Witte, T. de, Amadori, S., Willemze, R., and Baron, F.
- Published
- 2017
16. Low dose clofarabine in combination with a standard remission induction in patients 18-60 years with previously untreated intermediate and bad risk AML or high risk MDS:combined Phase I/II results of the EORTC/GIMEMA AML-14A Trial
- Author
-
Selleslag, D, Suciu, S, Meloni, G, Muus, P, Halkes, C, Venditti, A, Ramadan, S, Pruijt, H, Meert, L, Vignetti, M, Marie, J, Wittnebel, S, de Witte, T, Amadori, S, Willemze, R, and Baron, F
- Subjects
Settore MED/15 - Malattie del Sangue - Published
- 2017
17. A BIOPSYCHOSOCIAL APPROACH TO PHENOTYPE KNEE OSTEOARTHRITIS PATIENTS AWAITING TOTAL KNEE ARTHROPLASTY: A CROSS-SECTIONAL STUDY.
- Author
-
Vervullens, S., Meert, L., Van der Nest, G., Verbrugghe, J., Verdonk, P., Rahussen, F., Smeets, R., and Meeus, M.
- Published
- 2023
- Full Text
- View/download PDF
18. Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial
- Author
-
Selleslag, D., Suciu, S., Meloni, G., Muus, P., Halkes, C.J., Venditti, A., Ramadan, S.M., Pruijt, H., Meert, L., Vignetti, M., Marie, J.P., Wittnebel, S., Witte, T.J. de, Amadori, S., Willemze, R., Baron, F., Selleslag, D., Suciu, S., Meloni, G., Muus, P., Halkes, C.J., Venditti, A., Ramadan, S.M., Pruijt, H., Meert, L., Vignetti, M., Marie, J.P., Wittnebel, S., Witte, T.J. de, Amadori, S., Willemze, R., and Baron, F.
- Abstract
Contains fulltext : 169738.pdf (publisher's version ) (Open Access)
- Published
- 2017
19. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients
- Author
-
Viscoli, C., Herbrecht, R., Akan, H., Baila, L., Sonet, A., Gallamini, A., Giagounidis, A., Marchetti, O., Martino, R., Meert, L., Paesmans, M., Ameye, L., Shivaprakash, M., Ullmann, A. J., Maertens, J., Viscoli, C., Herbrecht, R., Akan, H., Baila, L., Sonet, A., Gallamini, A., Giagounidis, A., Marchetti, O., Martino, R., Meert, L., Paesmans, M., Ameye, L., Shivaprakash, M., Ullmann, A. J., and Maertens, J.
- Abstract
Objectives Caspofungin was evaluated as first-line monotherapy of invasive aspergillosis (IA) in patients with haematological malignancies and undergoing autologous transplants. Methods Adults with proven or probable IA, defined strictly according to EORTC-MSG criteria, were eligible. Those with possible IA were enrolled, but were not evaluable for efficacy unless upgraded to proven/probable disease within 7 days of registration based on investigations performed within 48 h after enrolment. Caspofungin dosage was 70 mg (day 1) followed by 50 mg/day. The primary endpoint was the proportion of patients with complete or partial response at the end of caspofungin therapy in the modified intention to treat (MITT) group; secondary endpoints were response and survival at day 84 and safety. Results In the MITT group (n = 61), 75% of patients had cancer not in remission (relapsing or refractory), 85% were neutropenic at enrolment and 49% had a Karnofsky score of ≤50. At end of treatment, 1 and 19 patients had complete and partial response, respectively [success rate 33% (20/61)], 9 (15%) achieved stabilization and 31 (51%) had disease progression. One patient was not evaluable. The 6 and 12 week survival rates were 66% (40/61) and 53% (32/60), respectively. Baseline characteristics associated with survival at day 84 were an underlying disease in remission (not relapsing or refractory) and Karnofsky score. Recovery from neutropenia at the end of treatment was also significantly associated with survival. No serious drug-related adverse events or discontinuations due to drug-related adverse events were observed. Conclusions Caspofungin provided an observed response rate compatible with the null hypothesis of a true response rate of ≤35%. Underlying disease-related factors had a major impact on results
- Published
- 2017
20. Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
- Author
-
Amadori, S., Suciu, S., Selleslag, D., Aversa, F., Gaidano, G., Musso, M., Annino, L., Venditti, A., Voso, M.T., Mazzone, C., Magro, D., Fabritiis, P. De, Muus, P., Alimena, G., Mancini, M., Hagemeijer, A., Paoloni, F., Vignetti, M., Fazi, P., Meert, L., Ramadan, S.M., Willemze, R., Witte, T.J. de, Baron, F., Amadori, S., Suciu, S., Selleslag, D., Aversa, F., Gaidano, G., Musso, M., Annino, L., Venditti, A., Voso, M.T., Mazzone, C., Magro, D., Fabritiis, P. De, Muus, P., Alimena, G., Mancini, M., Hagemeijer, A., Paoloni, F., Vignetti, M., Fazi, P., Meert, L., Ramadan, S.M., Willemze, R., Witte, T.J. de, and Baron, F.
- Abstract
Item does not contain fulltext, PURPOSE: To compare single-agent gemtuzumab ozogamicin (GO) with best supportive care (BSC) including hydroxyurea as first-line therapy in older patients with acute myeloid leukemia unsuitable for intensive chemotherapy. PATIENTS AND METHODS: In this trial, patients at least 61 years old were centrally randomized (1:1) to receive either a single induction course of GO (6 mg/m(2) on day 1 and 3 mg/m(2) on day 8) or BSC. Patients who did not progress after GO induction could receive up to eight monthly infusions of the immunoconjugate at 2 mg/m(2). Randomization was stratified by age, WHO performance score, CD33 expression status, and center. The primary end point was overall survival (OS) by intention-to-treat analysis. RESULTS: A total of 237 patients were randomly assigned (118 to GO and 119 to BSC). The median OS was 4.9 months (95% CI, 4.2 to 6.8 months) in the GO group and 3.6 months (95% CI, 2.6 to 4.2 months) in the BSC group (hazard ratio, 0.69; 95% CI, 0.53 to 0.90; P = .005); the 1-year OS rate was 24.3% with GO and 9.7% with BSC. The OS benefit with GO was consistent across most subgroups, and was especially apparent in patients with high CD33 expression status, in those with favorable/intermediate cytogenetic risk profile, and in women. Overall, complete remission (CR [complete remission] + CRi [CR with incomplete recovery of peripheral blood counts]) occurred in 30 of 111 (27%) GO recipients. The rates of serious adverse events (AEs) were similar in the two groups, and no excess mortality from AEs was observed with GO. CONCLUSION: First-line monotherapy with low-dose GO, as compared with BSC, significantly improved OS in older patients with acute myeloid leukemia who were ineligible for intensive chemotherapy. No unexpected AEs were identified and toxicity was manageable.
- Published
- 2016
21. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013)
- Author
-
Witte, T.J.M. de, Suciu, S., Meert, L., Halkes, C., Selleslag, D., Bron, D., Amadori, S., Willemze, R., Muus, P., Baron, F., Witte, T.J.M. de, Suciu, S., Meert, L., Halkes, C., Selleslag, D., Bron, D., Amadori, S., Willemze, R., Muus, P., and Baron, F.
- Abstract
Contains fulltext : 152324.pdf (publisher's version ) (Open Access), The primary objective of this trial was to assess the feasibility, toxicity profile, and antitumor activity of gemtuzumab ozogamicin (GO) combined with a chemotherapy remission-induction regimen in adults with untreated high-risk myelodysplastic syndrome (HR-MDS) or secondary acute myeloid leukemia (sAML). In this phase II trial, 30 patients with median age of 58 years received 1 day of GO as a 1-h infusion at the dose level of 5 mg/m(2) on day 7 of the remission-induction course further consisting of a continuous infusion of cytarabine 100 mg/m(2)/day for 10 days and idarubicin 12 mg/m(2)/day on days 1, 3, and 5. A consolidation course, consisting of intermediate-dose cytarabine (A) and idarubicin (I) followed by hematopoietic stem cell transplantation (HSCT) was planned for patients in complete remission (CR). The primary endpoints were response rate (CR/CRi) and severe toxicity rate. The secondary endpoint(s) were survival and progression-free survival (PFS) from start of treatment. Thirteen patients (43 %) achieved CR (eight patients) or CR with incomplete hematopoietic recovery (CRi) (five patients). In patients who achieved CR or CRi, the median time to recovery of neutrophils to 0.5 x 10(9)/l and of platelets to >50 x 10(9)/l was 29 and 30 days, respectively. Grade 3 to 4 severe toxicities occurred in nine patients. The most prominent was liver toxicity, as shown by elevated bilirubin levels in 16 patients and one case of nonfatal veno-occlusive disease (VOD). All 13 patients with CR/CRi received consolidation therapy, which was followed by allogeneic HSCT in five patients and autologous HSCT in three patients. According to the statistical design of the study, the idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) regimen did not show sufficient activity to warrant further exploration of this regimen in adult patients with HR-MDS or sAML.
- Published
- 2015
22. Reference values of a conditioned pain modulation paradigm using heat thermodes.
- Author
-
Meert, L., Vervullens, S., Smeets, R., and Meeus, M.
- Subjects
- *
REFERENCE values , *HEAT , *CONFERENCES & conventions , *PAIN threshold , *CONDITIONED response - Abstract
Introduction: The aim of this cross-sectional study is to provide reference values of a conditioned pain modulation (CPM) paradigm using thermal stimulation. Reference values would allow patient phenotyping according to their CPM functional status and can hopefully improve the ability to predict the efficacy of treatments. Methods: Healthy pain-free adults will be recruited. A CPM paradigm using heat thermodes will be applied. The intensity of the test stimulus (TS) will be determined individually based on a NRS score of 4/10. The conditioning stimulus (CS) will be 0.5°C higher than the TS temperature. The CPM effect will be reported both as absolute difference between the NRS scores during and before the CS, as well as the percent change from baseline (1). Influencing factors that will be considered are: age, gender, level of physical activity, chronic stress, intake of oral contraceptives, attentional focus, pain perception and phase of menstrual cycle (2). Results: We expect the average NRS score to decrease after the CS (= positive CPM effect). Discussion: To our knowledge, the present study will be the first one that specifically tries to determine reference values of CPM in pain-free adults using heat for both the TS and CS. However, it is important to note that the reliability and validity of the CPM paradigm used in this study has not been investigated yet. Process evaluation: Subject recruitment has just started and it is clear that successful recruitment will be the most difficult aspect of this study due to the strict inclusion criteria and the current Covid-19 situation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. Clofarabine in Combination with a Standard Remission Induction Regimen (AraC and idarubicin) in Patients with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Phase I Results of An Ongoing Phase I/II Study of the EORTC-LG and GIMEMA(EORTC GIMEMA 06061/AML-14A trial)
- Author
-
Willemze, R., Muus, P., Halkes, S.J.M., Meloni, G., Suciu, S., Meert, L., Flament, J., Karrasch, M., Vignetti, M., Amadori, S., Witte, T.M. de, and Marie, J.P.
- Published
- 2011
24. Patient- and Family-Centered Care as an approach to reducing disparities in asthma outcomes in urban African American children: A review of the literature
- Author
-
Harper, Felicity W.K., primary, Eggly, Susan, additional, Crider, Beverly, additional, Kobayashi, Hitomi, additional, Kathleen, R.N., additional, Meert, L., additional, Ball, Allison, additional, Penner, Louis A., additional, Gray, Herman, additional, and Albrecht, Terrance L., additional
- Published
- 2015
- Full Text
- View/download PDF
25. Indirect selection of industrial tomato genotypes that are resistant to spider mites (Tetranychus urticae)
- Author
-
Baier, J.E., primary, Resende, J.T.V., additional, Faria, M.V., additional, Schwarz, K., additional, and Meert, L., additional
- Published
- 2015
- Full Text
- View/download PDF
26. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organization for Research and Treatment of Cancer
- Author
-
Herbrecht, R, Maertens, J, Baila, L, Aoun, M, Heinz, W, Martino, R, Schwartz, S, Ullmann, Aj, Meert, L, Paesmans, M, Marchetti, O, Akan, H, Ameye, L, Shivaprakash, M, and Viscoli, Claudio
- Published
- 2010
27. High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial
- Author
-
Willemze, R., Suciu, S., Meloni, G., Labar, B., Marie, J.P., Halkes, C.J., Muus, P., Mistrik, M., Amadori, S., Specchia, G., Fabbiano, F., Nobile, F., Sborgia, M., Camera, A., Selleslag, D.L., Lefrere, F., Sr., Magro, D., Sica, S., Cantore, N., Beksac, M., Berneman, Z., Thomas, X., Melillo, L., Guimaraes, J.E., Leoni, P., Luppi, M., Mitra, M.E., Bron, D., Fillet, G., Marijt, E.W., Venditti, A., Hagemeijer, A., Mancini, M., Jansen, J.H., Cilloni, D., Meert, L., Fazi, P., Vignetti, M., Trisolini, S.M., Mandelli, F., Witte, T.J. de, Willemze, R., Suciu, S., Meloni, G., Labar, B., Marie, J.P., Halkes, C.J., Muus, P., Mistrik, M., Amadori, S., Specchia, G., Fabbiano, F., Nobile, F., Sborgia, M., Camera, A., Selleslag, D.L., Lefrere, F., Sr., Magro, D., Sica, S., Cantore, N., Beksac, M., Berneman, Z., Thomas, X., Melillo, L., Guimaraes, J.E., Leoni, P., Luppi, M., Mitra, M.E., Bron, D., Fillet, G., Marijt, E.W., Venditti, A., Hagemeijer, A., Mancini, M., Jansen, J.H., Cilloni, D., Meert, L., Fazi, P., Vignetti, M., Trisolini, S.M., Mandelli, F., and Witte, T.J. de
- Abstract
Item does not contain fulltext, PURPOSE: Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for remission induction. Consensus has not been reached on the benefit of higher dosages of cytarabine. PATIENTS AND METHODS: The European Organisation for Research and Treatment of Cancer (EORTC) and Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Leukemia Groups conducted a randomized trial (AML-12; Combination Chemotherapy, Stem Cell Transplant and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia) in 1,942 newly diagnosed patients with AML, age 15 to 60 years, comparing remission induction treatment containing daunorubicin, etoposide, and either standard-dose (SD) cytarabine (100 mg/m(2) per day by continuous infusion for 10 days) or high-dose (HD) cytarabine (3,000 mg/m(2) every 12 hours by 3-hour infusion on days 1, 3, 5, and 7). Patients in complete remission (CR) received a single consolidation cycle containing daunorubicin and intermediate-dose cytarabine (500 mg/m(2) every 12 hours for 6 days). Subsequently, a stem-cell transplantation was planned. The primary end point was survival. RESULTS: At a median follow-up of 6 years, overall survival was 38.7% for patients randomly assigned to SD cytarabine and 42.5% for those randomly assigned to HD cytarabine (log-rank test P = .06; multivariable analysis P = .009). For patients younger than age 46 years, survival was 43.3% and 51.9%, respectively (P = .009; multivariable analysis P = .003), and for patients age 46 to 60 years, survival was 33.9% and 32.9%, respectively (P = .91). CR rates were 72.0% and 78.7%, respectively (P < .001) and were 75.6% and 82.4% for patients younger than age 46 years (P = .01) and 68.3% and 74.8% for patients age 46 years and older (P = .03). Patients of all ages with very-bad-risk cytogenetic abnormalities and/or FLT3-ITD (internal tandem duplication) mutation, or with sec
- Published
- 2014
28. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
- Author
-
Willemze, Roel, Suciu, Stefan, Meloni, Giovanna, Labar, Boris, Marie, Jean Pierre, Halkes, Constantijn CJ, Muus, Petra, Mistrik, Martin, Amadori, Sergio, Specchia, Giorgina, Fabbiano, Francesco, Nobile, Francesco, Sborgia, Marco, Camera, Andrea, Selleslag, Dominik, Lefrère, Francois, Magro, Domenico, Sica, Simona, Cantore, Nicola, Beksac, Meral Sinan, Berneman, Zwi, Thomas, Xavier, Melillo, Lorella, Guimaraes, Jose E, Leoni, Pietro, Luppi, Mario, Mitra, Maria E, Bron, Dominique, Fillet, Georges, Marijt, Erik EW, Venditti, Adriano, Hagemeijer, Anne, Mancini, M., Jansen, Joop, Cilloni, Daniela, Meert, L, Fazi, Paola, Vignetti, Marco, Trisolini, Silvia SM, Mandelli, Franco, De Witte, Theo, Willemze, Roel, Suciu, Stefan, Meloni, Giovanna, Labar, Boris, Marie, Jean Pierre, Halkes, Constantijn CJ, Muus, Petra, Mistrik, Martin, Amadori, Sergio, Specchia, Giorgina, Fabbiano, Francesco, Nobile, Francesco, Sborgia, Marco, Camera, Andrea, Selleslag, Dominik, Lefrère, Francois, Magro, Domenico, Sica, Simona, Cantore, Nicola, Beksac, Meral Sinan, Berneman, Zwi, Thomas, Xavier, Melillo, Lorella, Guimaraes, Jose E, Leoni, Pietro, Luppi, Mario, Mitra, Maria E, Bron, Dominique, Fillet, Georges, Marijt, Erik EW, Venditti, Adriano, Hagemeijer, Anne, Mancini, M., Jansen, Joop, Cilloni, Daniela, Meert, L, Fazi, Paola, Vignetti, Marco, Trisolini, Silvia SM, Mandelli, Franco, and De Witte, Theo
- Abstract
Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for remission induction. Consensus has not been reached on the benefit of higher dosages of cytarabine., info:eu-repo/semantics/published
- Published
- 2014
29. High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial
- Author
-
Willemze, R, Suciu, S, Meloni, G, Labar, B, Marie, J, Halkes, Cjm, Muus, P, Mistrik, M, Amadori, S, Specchia, G, Fabbiano, F, Nobile, F, Sborgia, M, Camera, A, Selleslag, Dld, Lefrère, F, Magro, D, Sica, Simona, Cantore, N, Beksac, M, Berneman, Z, Thomas, X, Melillo, L, Guimaraes, Je, Leoni, P, Luppi, M, Mitra, Me, Bron, D, Fillet, G, Marijt, Ewa, Venditti, A, Hagemeijer, A, Mancini, M, Jansen, J, Cilloni, D, Meert, L, Fazi, P, Vignetti, M, Trisolini, Sm, Mandelli, F, De Witte, T., Sica, Simona (ORCID:0000-0003-2426-3465), Willemze, R, Suciu, S, Meloni, G, Labar, B, Marie, J, Halkes, Cjm, Muus, P, Mistrik, M, Amadori, S, Specchia, G, Fabbiano, F, Nobile, F, Sborgia, M, Camera, A, Selleslag, Dld, Lefrère, F, Magro, D, Sica, Simona, Cantore, N, Beksac, M, Berneman, Z, Thomas, X, Melillo, L, Guimaraes, Je, Leoni, P, Luppi, M, Mitra, Me, Bron, D, Fillet, G, Marijt, Ewa, Venditti, A, Hagemeijer, A, Mancini, M, Jansen, J, Cilloni, D, Meert, L, Fazi, P, Vignetti, M, Trisolini, Sm, Mandelli, F, De Witte, T., and Sica, Simona (ORCID:0000-0003-2426-3465)
- Abstract
Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for remission induction. Consensus has not been reached on the benefit of higher dosages of cytarabine.
- Published
- 2014
30. Fast full-wave validation of a metamaterial Luneburg lens
- Author
-
Bogaert, Ignace, MEERT, L, and Olyslager, Femke
- Subjects
Technology and Engineering - Published
- 2007
31. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients
- Author
-
UCL, UCL - (MGD) Service d'hématologie, UCL - (MGD) Service de médecine nucléaire, Viscoli, C., Herbrecht, R., Akan, H., Baila, L., Sonet, Anne, Gallamini, A., Giagounidis, A., Marchetti, O., Martino, R., Meert, L., Paesmans, M., Ameye, L., Shivaprakash, M., Ullmann, A. J., Maertens, Johan, UCL, UCL - (MGD) Service d'hématologie, UCL - (MGD) Service de médecine nucléaire, Viscoli, C., Herbrecht, R., Akan, H., Baila, L., Sonet, Anne, Gallamini, A., Giagounidis, A., Marchetti, O., Martino, R., Meert, L., Paesmans, M., Ameye, L., Shivaprakash, M., Ullmann, A. J., and Maertens, Johan
- Abstract
Caspofungin was evaluated as first-line monotherapy of invasive aspergillosis (IA) in patients with haematological malignancies and undergoing autologous transplants. Adults with proven or probable IA, defined strictly according to EORTC-MSG criteria, were eligible. Those with possible IA were enrolled, but were not evaluable for efficacy unless upgraded to proven/probable disease within 7 days of registration based on investigations performed within 48 h after enrolment. Caspofungin dosage was 70 mg (day 1) followed by 50 mg/day. The primary endpoint was the proportion of patients with complete or partial response at the end of caspofungin therapy in the modified intention to treat (MITT) group; secondary endpoints were response and survival at day 84 and safety. In the MITT group (n = 61), 75% of patients had cancer not in remission (relapsing or refractory), 85% were neutropenic at enrolment and 49% had a Karnofsky score of < 50. At end of treatment, 1 and 19 patients had complete and partial response, respectively [success rate 33% (20/61)], 9 (15%) achieved stabilization and 31 (51%) had disease progression. One patient was not evaluable. The 6 and 12 week survival rates were 66% (40/61) and 53% (32/60), respectively. Baseline characteristics associated with survival at day 84 were an underlying disease in remission (not relapsing or refractory) and Karnofsky score. Recovery from neutropenia at the end of treatment was also significantly associated with survival. No serious drug-related adverse events or discontinuations due to drug-related adverse events were observed. Caspofungin provided an observed response rate compatible with the null hypothesis of a true response rate of < 35%. Underlying disease-related factors had a major impact on results.
- Published
- 2009
32. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.
- Author
-
Viscoli, Claudio, Herbrecht, R, Akan, Hamdi, Baila, L., Sonet, Alexis, Gallamini, A, Giagounidis, A, Marchetti, Oscar, Martino, Robert, Meert, L, Paesmans, Marianne, Ameye, Lieveke, Shivaprakash, M, Ullmann, Andrew, Maertens, J., Infectious Disease Group of the EORTC, Viscoli, Claudio, Herbrecht, R, Akan, Hamdi, Baila, L., Sonet, Alexis, Gallamini, A, Giagounidis, A, Marchetti, Oscar, Martino, Robert, Meert, L, Paesmans, Marianne, Ameye, Lieveke, Shivaprakash, M, Ullmann, Andrew, Maertens, J., and Infectious Disease Group of the EORTC
- Abstract
Caspofungin was evaluated as first-line monotherapy of invasive aspergillosis (IA) in patients with haematological malignancies and undergoing autologous transplants., Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2009
33. Experimentally generated footprints in sand: Analysis and consequences for the interpretation of fossil and forensic footprints
- Author
-
D'Août, K., primary, Meert, L., additional, Van Gheluwe, B., additional, De Clercq, D., additional, and Aerts, P., additional
- Published
- 2009
- Full Text
- View/download PDF
34. Fast full-wave validation of a metamaterial Luneberg lens
- Author
-
Bogaert, I., primary, Meert, L., additional, and Olyslager, F., additional
- Published
- 2007
- Full Text
- View/download PDF
35. Characterization of speckle/despeckling in active millimeter wave imaging systems using a first order 1.5D model
- Author
-
Ocket, I., primary, Nauwelaers, B., additional, Fostier, J., additional, Meert, L., additional, Olyslager, F., additional, Koers, G., additional, Stiens, J., additional, Vounckx, R., additional, and Jager, I., additional
- Published
- 2006
- Full Text
- View/download PDF
36. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients
- Author
-
Viscoli, C., Herbrecht, R., Akan, H., Baila, L., Sonet, A., Gallamini, A., Giagounidis, A., Marchetti, O., Martino, R., Meert, L., Paesmans, M., Ameye, L., Shivaprakash, M., Ullmann, A. J., Maertens, J., Viscoli, C., Herbrecht, R., Akan, H., Baila, L., Sonet, A., Gallamini, A., Giagounidis, A., Marchetti, O., Martino, R., Meert, L., Paesmans, M., Ameye, L., Shivaprakash, M., Ullmann, A. J., and Maertens, J.
- Abstract
Objectives Caspofungin was evaluated as first-line monotherapy of invasive aspergillosis (IA) in patients with haematological malignancies and undergoing autologous transplants. Methods Adults with proven or probable IA, defined strictly according to EORTC-MSG criteria, were eligible. Those with possible IA were enrolled, but were not evaluable for efficacy unless upgraded to proven/probable disease within 7 days of registration based on investigations performed within 48 h after enrolment. Caspofungin dosage was 70 mg (day 1) followed by 50 mg/day. The primary endpoint was the proportion of patients with complete or partial response at the end of caspofungin therapy in the modified intention to treat (MITT) group; secondary endpoints were response and survival at day 84 and safety. Results In the MITT group (n = 61), 75% of patients had cancer not in remission (relapsing or refractory), 85% were neutropenic at enrolment and 49% had a Karnofsky score of ≤50. At end of treatment, 1 and 19 patients had complete and partial response, respectively [success rate 33% (20/61)], 9 (15%) achieved stabilization and 31 (51%) had disease progression. One patient was not evaluable. The 6 and 12 week survival rates were 66% (40/61) and 53% (32/60), respectively. Baseline characteristics associated with survival at day 84 were an underlying disease in remission (not relapsing or refractory) and Karnofsky score. Recovery from neutropenia at the end of treatment was also significantly associated with survival. No serious drug-related adverse events or discontinuations due to drug-related adverse events were observed. Conclusions Caspofungin provided an observed response rate compatible with the null hypothesis of a true response rate of ≤35%. Underlying disease-related factors had a major impact on results
37. A biopsychosocial approach to phenotyping people with knee osteoarthritis awaiting total knee arthroplasty: A secondary cohort analysis.
- Author
-
Vervullens S, Meert L, Smeets RJEM, van der Nest G, Verbrugghe J, Verdonk P, Rahusen FTG, and Meeus M
- Abstract
Background: Previous research showed chronic post-total knee arthroplasty (TKA) pain in 20% of people with knee osteoarthritis (KOA). Various preoperative biopsychosocial-related factors have been described, but phenotyping people with KOA awaiting TKA based on these factors is still lacking. This could be relevant to understanding differences in TKA surgery responses., Objective: To identify phenotypes in people with KOA awaiting TKA and differences in post-TKA pain based on preoperative biopsychosocial factors., Methods: People with KOA awaiting TKA in 4 hospitals in Belgium and the Netherlands were included. A cross-sectional latent profile analysis was conducted on structural, metabolic, functional, pain-related, psychological and social variables. Concurrent validity was tested using 3-step multinomial logistic regression. The difference in one-year post-TKA pain was examined with linear mixed model analysis., Results: Two hundred and seventeen participants were included in the latent profile analysis with a mean (SD) age of 65.5 (7.7) years, including 109 women. A model with 2 phenotypes differed in 14 out of 21 variables. Participants with phenotype 2 (28%) had a higher body mass index (BMI), higher chance of having less structural damage (KOA grade), lower mean quadriceps strength and physical function (Knee Society Scoring System functional and 30-second chair stand test), higher pain intensity, number of pain locations, and indices of central sensitisation (temporal summation, central sensitisation inventory score, and lower pressure pain thresholds), higher pain catastrophising, anxiety and depression, and higher post-TKA pain intensity compared to phenotype 1 (72%). Concurrent validity was confirmed in 3 out of 4 variables., Conclusions: Phenotype 2 (28%) with nociplastic pain characteristics in combination with worse psychological factors, BMI, functional and structural factors, and phenotype 1 (72%) not representing these characteristics were identified. Phenotype 2 had worse pain intensity scores after TKA compared to phenotype 1. Attention to the characteristics of phenotype 2 is warranted concerning post-TKA pain., Database Registration: The protocol is registered at ClinicalTrials.gov (NCT05380648)., Competing Interests: Declaration of competing interest Author R.J.E.M. received a grant from the Global Awards for Advancing Chronic Pain Research (ADVANCE) 2021 ID#70107413, however, this grant was not used for the current study. The other authors have no conflict of interest to declare, (Copyright © 2024 Elsevier Masson SAS. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
38. Application of the IASP Grading System to Identify Underlying Pain Mechanisms in Patients With Knee Osteoarthritis: A Prospective Cohort Study.
- Author
-
Vervullens S, Meert L, Meeus M, Heusdens CHW, Verdonk P, Foubert A, Abatih E, Durnez L, Verbrugghe J, and Smeets RJEM
- Subjects
- Humans, Female, Male, Prospective Studies, Aged, Middle Aged, Longitudinal Studies, Pain, Postoperative diagnosis, Pain, Postoperative physiopathology, Pain, Postoperative psychology, Severity of Illness Index, Belgium, Netherlands, Pain diagnosis, Pain physiopathology, Pain etiology, Osteoarthritis, Knee surgery, Osteoarthritis, Knee complications, Osteoarthritis, Knee physiopathology, Pain Measurement methods, Arthroplasty, Replacement, Knee
- Abstract
Objectives: This study aimed to apply the International Association for the Study of Pain (IASP) grading system for identifying nociplastic pain in knee osteoarthritis (KOA) awaiting total knee arthroplasty (TKA) and propose criteria to fine-tune decision-making. In addition, the study aimed to characterize a "probable" versus "no or possible" nociplastic pain mechanism using biopsychosocial variables and compare both groups in their 1-year post-TKA response., Methods: A secondary analysis of baseline data of a longitudinal prospective study involving 197 patients with KOA awaiting total TKA in Belgium and the Netherlands was performed. Two approaches, one considering 4 and the other 3 pain locations (step 2 of the grading system), were presented. Linear mixed model analyses were performed to compare the probable and no or possible nociplastic pain mechanism groups for several preoperative biopsychosocial-related variables and 1-year postoperative pain. Also, a sensitivity analysis, comparing 3 pain mechanism groups, was performed., Results: Thirty (15.22%-approach 4 pain locations) and 46 (23.35%-approach 3 pain locations) participants were categorized under probable nociplastic pain. Irrespective of the pain location approach or sensitivity analysis, the probable nociplastic pain group included more woman, was younger, exhibited worse results on various preoperative pain-related and psychological variables, and had more pain 1-year post-TKA compared with the other group., Discussion: This study proposed additional criteria to fine-tune the grading system for nociplastic pain (except for discrete/regional/multifocal/widespread pain) and characterized a subgroup of patients with KOA with probable nociplastic pain. Future research is warranted for further validation., Competing Interests: The authors declare no conflict of interest., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
39. Unravelling relationships between obesity, diabetes, and factors related to somatosensory functioning in knee osteoarthritis patients.
- Author
-
Meert L, Vervullens S, Heusdens CHW, Smeets RJEM, Meeus M, and Mertens MGCAM
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Cross-Sectional Studies, Prospective Studies, Netherlands, Belgium, Pain Threshold, Diabetes Mellitus physiopathology, Pain Measurement, Osteoarthritis, Knee physiopathology, Obesity physiopathology, Obesity complications, Body Mass Index, Glycated Hemoglobin metabolism
- Abstract
Objective: This study explores the association between obesity, diabetes, and somatosensory functioning in patients with knee osteoarthritis (OA), aiming to understand how metabolic conditions are related to pain mechanisms in this patient population. We hypothesized that higher body mass index (BMI), fat mass, and glycated hemoglobin levels (HbA1c) are associated with signs of altered somatosensory functioning., Methods: A cross-sectional analysis was conducted as part of a larger multicentre prospective cohort study. Data were collected from patients awaiting total knee arthroplasty in Belgium and the Netherlands. Associations between BMI, fat mass, HbA1c, and various pain-related variables were examined employing Pearson and Spearman correlation analyses which were further analyzed with linear regression techniques., Results: The study included 223 participants. Analysis revealed a significant although weak negative correlation between fat mass and pressure pain thresholds (PPT) at multiple locations, suggesting a link between higher fat mass and increased mechanical hyperalgesia. There were no significant correlations between BMI and pain-related outcomes. HbA1c levels showed very weak positive correlations with pain measures but did not withstand correction for multiple testing., Conclusion: The findings indicate that fat mass may be closely associated with altered somatosensory functioning in patients with knee OA. However, no significant correlations were found between BMI or HbA1c levels and pain-related outcomes. Future research should focus on longitudinal studies to elucidate the causal relationships and further explore the impact of metabolic factors on pain mechanisms in this patient population. Key Points • The findings indicate that fat mass may be closely associated with altered somatosensory functioning in patients with knee OA., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
40. Does pain intensity after total knee arthroplasty depend on somatosensory functioning in knee osteoarthritis patients? A prospective cohort study.
- Author
-
Vervullens S, Meert L, Smeets RJEM, Verbrugghe J, Verdonk P, and Meeus M
- Subjects
- Humans, Female, Male, Prospective Studies, Aged, Middle Aged, Longitudinal Studies, Pain Threshold, Pain, Postoperative etiology, Belgium, Netherlands, Hyperalgesia physiopathology, Osteoarthritis, Knee surgery, Osteoarthritis, Knee physiopathology, Arthroplasty, Replacement, Knee, Pain Measurement
- Abstract
The objective of this study is to determine whether the change in pain intensity over time differs between somatosensory functioning evolution profiles in knee osteoarthritis (KOA) patients undergoing total knee arthroplasty (TKA). This longitudinal prospective cohort study, conducted between March 2018 and July 2023, included KOA patients undergoing TKA in four hospitals in Belgium and the Netherlands. The evolution of the Knee Injury and Osteoarthritis Outcome Score (KOOS) subscale pain over time (baseline, 3 months, and 1 year post-TKA scores) was the outcome variable. The evolution scores of quantitative sensory testing (QST) and Central Sensitization Inventory (CSI) over time (baseline and 1 year post-TKA scores) were used to make subgroups. Participants were divided into separate normal, recovered, and persistent disturbed somatosensory subgroups based on the CSI, local and widespread pressure pain threshold [PPT] and heat allodynia, temporal summation [TS], and conditioned pain modulation [CPM]. Linear mixed model analyses were performed. Two hundred twenty-three participants were included. The persistent disturbed somatosensory functioning group had less pronounced pain improvement (based on CSI and local heat allodynia) and worse pain scores 1 year post-TKA (based on CSI, local PPT and heat allodynia, and TS) compared to the normal somatosensory functioning group. This persistent group also had worse pain scores 1 year post-TKA compared to the recovered group (based on CSI). The study suggests the presence of a "centrally driven central sensitization" subgroup in KOA patients awaiting TKA in four of seven grouping variables, comprising their less pain improvement or worse pain score after TKA. Future research should validate these findings further. The protocol is registered at clinicaltrials.gov (NCT05380648)., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
41. Preoperative glycaemic control, number of pain locations, structural knee damage, self-reported central sensitisation, satisfaction and personal control are predictive of 1-year postoperative pain, and change in pain from pre- to 1-year posttotal knee arthroplasty.
- Author
-
Vervullens S, Meert L, Smeets RJEM, Verbrugghe J, Baert I, Rahusen FTG, Heusdens CHW, Verdonk P, and Meeus M
- Abstract
Purpose: The aim of this study was to identify preoperative predictors for 1-year posttotal knee arthroplasty (TKA) pain and pre- to post-TKA pain difference in knee osteoarthritis (KOA) patients., Methods: From March 2018 to July 2023, this prospective longitudinal cohort study enrolled KOA patients awaiting TKA from four hospitals in Belgium and the Netherlands. Different biopsychosocial predictors were assessed preoperatively by questionnaires and physical examinations (input variables). The Knee injury and Osteoarthritis Outcome Score (KOOS) subscale pain was used to measure pain intensity. The absolute KOOS subscale pain score 1-year post-TKA and the difference score (ΔKOOS = 1-year postoperative - preoperative) were used as primary outcome measures (output variables). Two multivariable linear regression analyses were performed., Results: Two hundred and twenty-three participants were included after multiple imputation. Worse absolute KOOS subscale pain scores 1-year post-TKA and negative or closer to zero ΔKOOS subscale pain scores were predicted by self-reported central sensitisation, lower KOA grade and preoperative satisfaction, and higher glycated haemoglobin, number of pain locations and personal control (adjusted R
2 = 0.25). Additional predictors of negative or closer to zero ΔKOOS subscale pain scores were being self-employed, higher preoperative pain and function (adjusted R2 = 0.37)., Conclusion: This study reports different biopsychosocial predictors for both outcomes that have filtered out other potential predictors and provide value for future studies on developing risk assessment tools for the prediction of chronic TKA pain., Protocol Registration: The protocol is registered at clinicaltrials.gov (NCT05380648) on 13 May 2022., Level of Evidence: Level II., (© 2024 The Authors. Knee Surgery, Sports Traumatology, Arthroscopy published by John Wiley & Sons Ltd on behalf of European Society of Sports Traumatology, Knee Surgery and Arthroscopy.)- Published
- 2024
- Full Text
- View/download PDF
42. Evolution of somatosensory processing signs after nociceptive targeted surgery in patients with musculoskeletal disorders: a systematic review.
- Author
-
Vervullens S, Meert L, Meeus M, Baert I, Heusdens CHW, Caethoven C, Charpentier N, Vervliet A, and Smeets RJEM
- Subjects
- Humans, Pain Measurement, Nociception, Pain, Postoperative diagnosis, Chronic Pain, Musculoskeletal Diseases
- Abstract
Abstract: Surgery is often advised when conservative treatment fails in musculoskeletal pain conditions, but a substantial proportion still suffers chronic pain after surgery. Somatosensory processing system (SPS) signs were previously studied as potential predictors for chronic postsurgical pain, but results are inconsistent. Therefore, studying the evolution of SPS signs could be of added value. The aim was to summarize all studies that measured how SPS signs evolved after nociceptive targeted surgery in musculoskeletal disorders and to find preoperative, perioperative, and postoperative predictors for the evolution of these SPS signs. Data were summarized, and risk of bias and level of evidence and recommendation were determined. Twenty-one studies were included. Five scored a low, 3 a moderate, and 13 a high risk of bias. In general, no consistent evolution of SPS signs comparing preoperative and postoperative values and predictors for this evolution in musculoskeletal disorders could be found. In most cases, static quantitative sensory testing (QST) did not change or conflicting results were found. On the other hand, dynamic QST mostly improved after surgery. Worthfully mentioning is that worsening of SPS signs was only seen at a follow-up of <3 months after surgery, that conclusions are stronger when evaluating dynamic QST with a follow-up of ≥3 months after surgery, and that pain improvement postsurgery was an important predictor. Future high-quality research should focus on the evolution of SPS signs after nociceptive targeted surgery, accounting for pain improvement groups and focusing on preoperative, perioperative, and postoperative predictors of this evolution., (Copyright © 2023 International Association for the Study of Pain.)
- Published
- 2023
- Full Text
- View/download PDF
43. The impact of COVID-19 lockdown on the general health status of people with chronic health conditions in Belgium: a cross-sectional survey study.
- Author
-
De Groef A, Hallemans A, Gebruers N, Meirte J, Saeys W, Truijen S, Haenen V, Johnson C, Meert L, Peeters L, Fransen E, Meeus M, and Durnez L
- Subjects
- Adult, Humans, Child, Cross-Sectional Studies, Belgium epidemiology, Communicable Disease Control, Health Status, COVID-19 epidemiology
- Abstract
Background: Patients with chronic health conditions risk aggravation of their health status due to reduced access to health services during the COVID-19 related lockdown., Objectives: To investigate the impact of Belgian COVID-19 measures on general health status (i.e. worse or stable/better) of patients, adult and pediatric, with chronic health conditions and how this change in health status relates to personal and health behavior-related factors., Design: A cross-sectional study using an online survey was conducted during the first COVID-19 related lockdown in Belgium., Methods: Associations between change in health status since the lockdown and (change in) personal and health behavior-related factors (including physical activity, access to health-care services and social activities) were investigated., Results: In adults (n = 561), almost all personal factors, including feelings of distress, depression, anxiety, somatization, and low self-efficacy, were significantly worse in patients with a worse health status during the lockdown (n = 293, 52%) compared to patients reporting a stable/better health status (p < .001-0.002). Also, these patients reported lower physical activity levels, more tele-consultations and less social activities (p < .001-0.006). In children (n = 55), all surveys were completed by a proxy (parent(s)/guardian) who reported a worse health status in 38% of the children. Level of distress of the child (p = .005) since the lockdown and somatization of the parent(s) (p = .0018) were significantly worse in children with a worse versus a stable/better health status., Conclusion: Fifty-two percent of the adults and 38% of children with chronic health conditions reported worsening of their general health status during the lockdown in March-May 2020 in Belgium. Negative personal factors and unhelpful health behavior seems to be associated with a worse health status.
- Published
- 2023
- Full Text
- View/download PDF
44. Identification of Metabolic Factors and Inflammatory Markers Predictive of Outcome after Total Knee Arthroplasty in Patients with Knee Osteoarthritis: A Systematic Review.
- Author
-
Meert L, Mertens MG, Meeus M, Vervullens S, Baert I, Beckwée D, Verdonk P, and Smeets RJEM
- Subjects
- Humans, Quality of Life, Outcome Assessment, Health Care, Longitudinal Studies, Treatment Outcome, Knee Joint, Arthroplasty, Replacement, Knee adverse effects, Osteoarthritis, Knee surgery
- Abstract
Objective: To identify metabolic factors and inflammatory markers that are predictive of postoperative total knee arthroplasty (TKA) outcome., Method: A systematic search of the existing literature was performed using the electronic databases PubMed, Web of Science and Embase until the 1
st of August 2022. Studies that evaluated the influence of metabolic or inflammatory markers (I) on postsurgical outcome (O) in end-stage knee osteoarthritis patients awaiting primary TKA (P) were included in this review., Results: In total, 49 studies were included. Risk of bias of the included studies was low for one study, moderate for 10 studies and high for the remaining 38 studies. Conflicting evidence was found for the influence of body mass index, diabetes, cytokine levels and dyslipidaemia on pain, function, satisfaction and quality of life at more than six months after TKA., Conclusions: Several limitations such as not taking into account known confounding factors, the use of many different outcome measures and a widely varying follow-up period made it challenging to draw firm conclusions and clinical implications. Therefore large-scaled longitudinal studies assessing the predictive value of metabolic and inflammatory factors pre-surgery in addition to the already evidenced risk factors with follow-up of one year after TKA are warranted.- Published
- 2023
- Full Text
- View/download PDF
45. Prehabilitation before total knee arthroplasty: A systematic review on the use and efficacy of stratified care.
- Author
-
Vervullens S, Meert L, Baert I, Smeets RJEM, Verdonk P, Rahusen F, and Meeus M
- Subjects
- Humans, Quality of Life, Preoperative Exercise, Prospective Studies, Pain etiology, Arthroplasty, Replacement, Knee adverse effects, Osteoarthritis, Knee rehabilitation
- Abstract
Background: Preoperative rehabilitation (hereafter called "prehabilitation") has been proposed as a potentially effective treatment to target preoperative risk factors to prevent insufficient outcome after total knee arthroplasty (TKA)., Purpose: We aimed to assess whether previous clinical trials of non-surgical, non-pharmacological prehabilitation in individuals with knee osteoarthritis (KOA) awaiting TKA focused on specific clinical phenotypes or specific individual characteristics and whether the content of the prehabilitation was stratified accordingly. Second, we aimed to summarize and compare the long-term effects of stratified and non-stratified care on pain, satisfaction, function and quality of life., Methods: A systematic literature search of PubMed, Web of Science, Scopus and Embase was performed. All relevant articles published up to April 19, 2021 reporting "(randomized controlled) clinical trials or prospective cohort studies" (S) related to the key words "total knee arthroplasty" (P), "preoperative conservative interventions" (I), "pain, function, quality of life and/or satisfaction" (O) were included., Results: After screening 3498 potentially eligible records, 18 studies were assessed for risk of bias. Twelve studies had low, 2 moderate, 3 serious, and one high risk of bias. The latter study was excluded, resulting in 17 included studies. Five studies investigated a"stratified prehabilitation care" and 12 "non-stratified prehabilitation care". Stratified prehabilitation in 4 studies meant that the study sample was chosen considering a predefined intervention, and in the fifth study, the prehabilitation was stratified to individuals' needs. No direct comparison between the 2 approaches was possible. We found weak evidence for a positive effect of biopsychosocial prehabilitation compared to no prehabilitation on function (stratified studies) and pain neuroscience education prehabilitation compared to biomedical education on satisfaction (non-stratified studies) at 6 months post-TKA. We found strong evidence for positive effects of exercise prehabilitation compared to no prehabilitation on pain at 6 months and on function at 12 months post-TKA (non-stratified studies)., Conclusion: More research is needed of stratified prehabilitation care focusing on individual characteristics in people with KOA awaiting TKA., Registration Number: This systematic review was prospectively registered at PROSPERO on March 22, 2021 (no. CRD42021221098)., Competing Interests: Conflict of interest None declared., (Copyright © 2022 Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
46. Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer.
- Author
-
Maertens J, Lodewyck T, Donnelly JP, Chantepie S, Robin C, Blijlevens N, Turlure P, Selleslag D, Baron F, Aoun M, Heinz WJ, Bertz H, Ráčil Z, Vandercam B, Drgona L, Coiteux V, Llorente CC, Schaefer-Prokop C, Paesmans M, Ameye L, Meert L, Cheung KJ, Hepler DA, Loeffler J, Barnes R, Marchetti O, Verweij P, Lamoth F, Bochud PY, Schwarzinger M, and Cordonnier C
- Subjects
- Humans, Antifungal Agents therapeutic use, Fluconazole therapeutic use, Caspofungin therapeutic use, Mycoses drug therapy, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute drug therapy, Myelodysplastic Syndromes
- Abstract
Background: Empiric antifungal therapy is considered the standard of care for high-risk neutropenic patients with persistent fever. The impact of a preemptive, diagnostic-driven approach based on galactomannan screening and chest computed tomography scan on demand on survival and on the risk of invasive fungal disease (IFD) during the first weeks of high-risk neutropenia is unknown., Methods: Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and allogeneic hematopoietic cell transplant recipients were randomly assigned to receive caspofungin empirically (arm A) or preemptively (arm B), while receiving fluconazole 400 mg daily prophylactically. The primary end point of this noninferiority study was overall survival (OS) 42 days after randomization., Results: Of 556 patients recruited, 549 were eligible: 275 in arm A and 274 in arm B. Eighty percent of the patients had AML or MDS requiring high-dose chemotherapy, and 93% of them were in the first induction phase. At day 42, the OS was not inferior in arm B (96.7%; 95% confidence interval [CI], 93.8%-98.3%) when compared with arm A (93.1%; 95% CI, 89.3%-95.5%). The rates of IFDs at day 84 were not significantly different, 7.7% (95% CI, 4.5%-10.8%) in arm B vs 6.6% (95% CI, 3.6%-9.5%) in arm A. The rate of patients who received caspofungin was significantly lower in arm B (27%) than in arm A (63%; P < .001)., Conclusions: The preemptive antifungal strategy was safe for high-risk neutropenic patients given fluconazole as prophylaxis, halving the number of patients receiving antifungals without excess mortality or IFDs. Clinical Trials Registration. NCT01288378; EudraCT 2010-020814-27., Competing Interests: Potential conflicts of interest. J. M. reports consulting fees and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from MSD, Gilead Sciences, and Pfizer, including participation on a data and safety monitoring board or advisory board (DSMB) for MSD, Gilead, and Pfizer. T. L. reports payment for participation on virtual European Society for Blood and Marrow Transplantation meeting. J. P. D. reports consulting fees from F2G and Gilead Sciences, including payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from F2G, Gilead Sciences, and Pfizer, and unpaid leadership or fiduciary role in other board, society, committee, or advocacy group for the European PCR Initiative Foundation. C. R. reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Gilead and Sandoz and support for attending meetings and/or travel for Gilead, MSD, Pfizer, and Sandoz. N. B. reports participation as the chair on a DSMB for the SHORT trial and roles as the president of the Dutch Society of Hematology (unpaid), Treasurer Board member for HOVON (unpaid), chair of the Horizonscan WP Hematology Dutch Healthcare Institute (vacancy fee), and member of the board of supervisors for Matchis (compensation according to Dutch law). D. S. reports grants or contracts from Pfizer, Novartis, BMS, AbbVie, MSD, and Takeda, including consulting fees from Pfizer, Novartis, AbbVie, BMS, Takeda, MSD, Janssen-Cilag, and Astellas; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Pfizer, Novartis, AbbVie, BMS, Takeda, MSD, and Janssen-Cilag; support for attending meetings and/or travel from Pfizer, Novartis, BMS, AbbVie, Takeda, MSD, and Janssen-Cilag; and a leadership or fiduciary role for other board, society, committee, or advocacy groups, paid or unpaid for Belgian College for Reimbursement of Orphan Drugs. F. B. reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AbbVie and Sanofi; support for attending an international meeting from Novartis and Pfizer; and participation on a DSMB or advisory board for some academic studies (no fee) and Maatpharma (paid to institution). W. J. H. reports payment or honoraria for presentations from AbbVie, Amgen, AstraZeneca, Celgene/BMS, Gilead Sciences, and Janssen; support for attending meetings from IPSEN Pharma, Amgen, and Abbvie; and support for attending adboards for Amgen, Astrazeneca, Celgene/BMS, Gilead Sciences Janssen, MSD, and Sanofi-Aventis. B. V. reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Pfizer, Sanofi, and Al Miral; support for attending meetings and/or travel for ViiV; and participation on a DSMB or advisory board for Pfizer. L. D. reports consulting fees from MSD, Pfizer, and Teva; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from MSD, Pfizer, Teva, and Sandoz; support for attending meetings and/or travel from Sandoz; and participation on an advisory board for Pfizer. C. C. L. reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Gilead and Kite and support for attending meetings and/or travel for Gilead and Kite. C. S. P. reports book royalties from Elsevier and Thieme and honoraria for lectures from Canon Medical Systems. R. B. reports consulting fees from Gilead; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Gilead; and support for attending meetings and/or travel for Gilead. P. E. V. reports research grants from ZonMw, Welcome Trust, Eurostars, EORTC, and RIVM; consulting fees from F2G, Gilead Sciences, and Pfizer; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Gilead Sciences and Pfizer. F. L. reports research grants from Merck, Sharpe & Dohme, Gilead, Pfizer, and Novartis and consulting fees (advisory board) from Gilead and Pfizer. P. Y. B. reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Gilead Sciences Switzerland AG and Pfizer PFE Switzerland GmbH and support for Gilead Sciences Switzerland Sarl for TIMM, Trends in Medical Mycology. D. H. reports employment with Merck & Co. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2023
- Full Text
- View/download PDF
47. Personal influencing factors for pressure pain threshold in healthy people: A systematic review and meta-analysis.
- Author
-
Vervullens S, Haenen V, Meert L, Meeus M, Smeets RJEM, Baert I, and Mertens MGCAM
- Subjects
- Bias, Female, Humans, Pain Measurement methods, Pain, Pain Threshold physiology
- Abstract
All studies that investigated personal factors influencing pressure pain threshold (PPT) in healthy people were synthesized. Data was summarized, and risk of bias (RoB) and level of evidence were determined. Results were pooled per influencing factor, grouped by body region and included in meta-analyses. Fifty-four studies were eligible. Five had low, nine moderate, and 40 high RoB. Following meta-analyses, a strong conclusion was found for the influence of scapular position, a moderate for the influence of gender, and a weak for the influence of age (shoulder/arm region) and blood pressure on PPT. In addition, body mass index, gender (leg region), alcohol consumption and pain vigilance may not influence PPT. Based on qualitative summary, depression and menopause may not influence PPT. For other variables there was only preliminary or conflicting evidence. However, caution is advised, since the majority of included studies showed a high RoB and several were not eligible to include in meta-analyses. Heterogeneity was high in the performed meta-analyses, and most conclusions were weak. More standardized research is necessary., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
48. Exercise Therapy Is Effective for Improvement in Range of Motion, Function, and Pain in Patients With Frozen Shoulder: A Systematic Review and Meta-analysis.
- Author
-
Mertens MG, Meert L, Struyf F, Schwank A, and Meeus M
- Subjects
- Exercise Therapy methods, Humans, Pain, Physical Therapy Modalities, Range of Motion, Articular, Bursitis therapy
- Abstract
Objective(s): To determine (1) the effect of exercise therapy alone or in combination with other interventions compared with solely exercises and programs with or without exercises and (2) what kind of exercise therapy or combination with other interventions is most effective., Data Sources: PubMed, Web of Science and Cochrane Central Register of Controlled Trials., Study Selection: Studies were screened in a 2-phase approach by 2 independent reviewers (M.M. and L.M.). Reference lists of included studies and interesting systematic reviews were hand searched., Data Extraction: Two independent reviewers (M.M. and L.M.) extracted information about origin, characteristics of study participants, eligibility criteria, characteristics of interventions, outcome measures and main results in a pre-defined template., Data Synthesis: Thirty-three studies were included in the qualitative and 19 in the meta-analysis. Preliminary evidence was found for supervised exercises to be more beneficial than home exercises for ROM and function. Multimodal programs comprising exercises may result in little to no difference in ROM compared to solely exercises. Programs comprising muscle energy techniques show little to no difference in ROM when compared with programs with other exercises. Adding stretches to a multimodal program with exercises may increase ROM. There is uncertain evidence that there is a difference between those programs regarding function and pain. Preliminary evidence was found for several treatment programs including exercises to be beneficial for improvement in both passive and active ROM, function, pain, and muscle strength. No studies used patient satisfaction as an outcome measure., Conclusions: ROM, function, and pain improve with both solely exercises and programs with exercises, but for ROM and pain there was little to no difference between programs and for function the evidence was uncertain. Adding exercises improve active ROM compared with a program without exercises, whereas adding physical modalities has no beneficial effect. Muscle energy techniques are a beneficial type of exercise therapy for improving function compared with other types of exercise. Unfortunately, no conclusion can be drawn about the results in the long-term and most effective dose of exercise therapy., (Copyright © 2021 The American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
49. The effect of one dry needling session on pain, central pain processing, muscle co-contraction and gait characteristics in patients with knee osteoarthritis: a randomized controlled trial.
- Author
-
Vervullens S, Meert L, Baert I, Delrue N, Heusdens CHW, Hallemans A, Van Criekinge T, Smeets RJEM, and De Meulemeester K
- Subjects
- Gait, Humans, Dry Needling, Neuralgia, Osteoarthritis, Knee therapy, Superficial Back Muscles
- Abstract
Objectives: To assess the immediate and three days postintervention effect of one dry needling session compared to one sham needling session on pain, central pain processing, muscle co-contraction and spatiotemporal parameters during gait in knee osteoarthritis patients., Methods: A double-blind randomized controlled trial was conducted. Sixty-one knee osteoarthritis patients were randomly assigned to the dry needling or sham needling group. Primary outcomes were pain and central pain processing. Secondary outcomes included muscle co-contraction and spatiotemporal parameters during gait. Patients were assessed at baseline and 15 min after the intervention, and pain also three days after the intervention. Linear mixed models were used to examine between- and within-group differences., Results: No significant between-group differences for pain were found, but within-group scores showed a significant decrease 15 min after sham needling and three days after dry needling. The mean conditioned pain modulation effect measured at the m. Trapezius worsened significantly 15 min after sham needling compared to after dry needling (between-group difference). However, individual conditioned pain modulation percentage scores remained stable over time. Various significant within-group differences were found 15 min after sham needling: a decrease of conditioned pain modulation measured at m. Quadriceps and m. Trapezius and stride- and step-time scores, and an increase in step length and widespread pain pressure threshold. A significant decrease in muscle co-contraction index of the m. Vastus Medialis and Semitendinosus was found as within-group difference 15 min after dry needling., Conclusions: Dry needling has no larger effect on pain, central pain processing, muscle co-contraction and gait pattern 15 min and three days postintervention compared to sham needling. Mean conditioned pain modulation scores worsened after sham needling compared to after dry needling. Further research remains necessary., (© 2021 Walter de Gruyter GmbH, Berlin/Boston.)
- Published
- 2021
- Full Text
- View/download PDF
50. Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials.
- Author
-
Ramadan SM, Suciu S, Stevens-Kroef MJPL, Willemze R, Amadori S, de Witte T, Löwenberg B, Muus P, Labar B, Meert L, de Schaetzen G, Meloni G, Leone G, Vignetti M, Marie JP, Lübbert M, and Baron F
- Abstract
We report the outcomes of secondary acute myeloid leukemia (s-AML) patients included in one of 13 European Organisation for Research and Treatment of Cancer (EORTC) collaborative AML trials using intensive remission-induction chemotherapy. Among 8858 patients treated between May 1986 and January 2008, 960 were identified as having s-AML, either after MDS (cohort A; n = 508), occurring after primary solid tumors or hematologic malignancies other than MDS (cohort B; n = 361), or after non-malignant conditions or with a history of toxic exposure (cohort C; n = 91). Median age was 64 years, 60 years and 61 years in cohort A, B and C, respectively. Among patients ≤60 years and classified in the cohorts A or B ( n = 367), the 5-year overall survival (OS) rate was 28%. There was a systematic improvement in the 5-year OS rate over three time periods ( p < 0.001): 7.7% (95% CI: 1.3-21.7%) for patients treated before 1990 (period 1: n = 26), 23.3% (95% CI: 17.1-30.0%) for those treated between 1990 and 2000 (period 2: n = 188) and 36.5% (95% CI: 28.7-44.3%) for those treated in 2000 or later (period 3: n = 153). In multivariate analysis, male gender (HR = 1.39; p = 0.01), WBC ≥ 25 × 10
9 /L (HR = 2.00; p < 0.0001), age 46-60 years (HR = 1.65; p < 0.001) and poor-risk cytogenetics (HR = 2.17; p < 0.0001) were independently associated with shorter OS, while being treated during period 2 (HR = 0.50, p = 0.003) or period 3 (HR = 0.43; p = 0.0008). Having received high-dose cytarabine (HD-AraC) ( n = 48) in the induction chemotherapy (HR = 0.54, p = 0.012) was associated with a longer OS. In contrast, among patients >60 years of age ( n = 502), the OS was dismal, and there was no improvement over time.- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.